北京大学血液病研究所造血干细胞移植北京重点室.pptVIP

Huang XJ, et al. BMT, 2006, 38:291 Huang XJ, et al. Blood, 2006, 107(8):3065-3073 Huang XJ, et al. Clin Cancer Res, 2009, 15: 4777-4783 Huang XJ, et al. BBMT. 2011 Feb;17(2):197-204 Part I Conclusions G-BM combined with PBSC from haploidentical family donors, without in vitro TCD, may be used as a good source of stem cells for allo-HSCT There is no difference in OS and LFS between patients receiving allografts from PMRD and URD 3. Unmanipulated Haploidentical HSCT 3.Unmanipulated Haploidentical HSCT Huang XJ, et al Unpublished，Blood Reversed Part II：Strategy to Improve the Clinical Results 1 Modified Donor Lymphocyte Infusion(DLI) 2 Manipulating the Graft 3 Optimize KIR ligand match/mismatch 4 Improve Immune Reconstitution 3. Unmanipulated Haploidentical HSCT Relapse Remains a Problem after HSCT High risk leukemia Huang XJ et al, Biol Blood Marrow Transplant. 2009 Feb;15(2) Especially for advanced leukemia (58%- 74%) 3. Unmanipulated Haploidentical HSCT Strategy-1 Our modified DLI G-CSF primed peripheral blood progenitor cells instead of steady donor lymphocyte harvests Short-term CsA/MTX for prevention of DLI-associated GVHD GPBSCI Huang XJ et al, LEUKEMIA, 2006；20，365-368 Huang XJ et al, Bone Marrow Transplant. 2009;44(5):309-16 3. Unmanipulated Haploidentical HSCT GVHD prophylaxis Reduced GVHD occurrence Huang XJ, et al. Hematologica, 2007,92:414-417 None MTX 3. Unmanipulated Haploidentical HSCT Prevention of relapse using modified DLI can significantly increase survival following HLA-mismatched/Haplo-identical HSCT in patients with advanced-stage, acute leukemia 3. Unmanipulated Haploidentical HSCT Huang XJ ,et al. Bone Marrow Transplant. 2011 Sep accepted Huang XJ ,et al. Bone Marrow Transplant. 2011 Sep accepted Diagnosis N=75 Jan,2003 - Sep,2010 AML N=42 CR2 7 NR+REL 35 ALL N=33 CR2 8 NR+REL 25 Patients Characteristic 3. Unmanipulated Haploidentical HSCT Prophylactic GPBPCI Performed at 70 (20 ~ 314) d after HSCT